(-0.04%) 5 243.25 points
(-0.01%) 39 557 points
(-0.11%) 18 276 points
(-0.01%) $79.11
(-0.80%) $2.36
(0.19%) $2 347.40
(0.34%) $28.54
(0.07%) $1 011.50
(0.06%) $0.927
(0.05%) $10.81
(0.01%) $0.796
(-0.27%) $91.35
Live Chart Being Loaded With Signals
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally...
Stats | |
---|---|
Today's Volume | 856 777 |
Average Volume | 2.11M |
Market Cap | 0.00 |
EPS | INR4.77 ( 2021-12-30 ) |
Last Dividend | INR3.50 ( 2021-07-29 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 7.43 |
ATR14 | INR0 (0.00%) |
Zydus Lifesciences Correlation
10 Most Positive Correlations | |
---|---|
BCG.NS | 0.954 |
TIDEWATER.NS | 0.948 |
TATVA.NS | 0.941 |
SINTEX.NS | 0.933 |
CLNINDIA.NS | 0.932 |
BUTTERFLY.NS | 0.932 |
INDLMETER.NS | 0.93 |
GILLETTE.NS | 0.929 |
DBL.NS | 0.927 |
AMBICAAGAR.NS | 0.925 |
10 Most Negative Correlations | |
---|---|
MUKANDENGG.NS | -0.954 |
JBMA.NS | -0.945 |
KIRLOSIND.NS | -0.939 |
GFSTEELS.NS | -0.937 |
FINCABLES.NS | -0.92 |
FOCUS.NS | -0.919 |
KEERTI.NS | -0.917 |
STAMPEDE.NS | -0.914 |
JSLHISAR.NS | -0.914 |
LINDEINDIA.NS | -0.913 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Zydus Lifesciences Financials
Annual | 2022 |
Revenue: | INR170.51B |
Gross Profit: | INR68.01B (39.89 %) |
EPS: | INR19.30 |
FY | 2022 |
Revenue: | INR170.51B |
Gross Profit: | INR68.01B (39.89 %) |
EPS: | INR19.30 |
FY | 2021 |
Revenue: | INR148.22B |
Gross Profit: | INR93.42B (63.03 %) |
EPS: | INR20.84 |
FY | 2020 |
Revenue: | INR138.12B |
Gross Profit: | INR86.63B (62.72 %) |
EPS: | INR11.49 |
Financial Reports:
No articles found.
Zydus Lifesciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.200 | 2000-05-02 |
Last Dividend | INR3.50 | 2021-07-29 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | INR96.45 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 1.87 | -- |
Div. Sustainability Score | 4.12 | |
Div.Growth Potential Score | 3.01 | |
Div. Directional Score | 3.57 | -- |
Year | Amount | Yield |
---|---|---|
2000 | INR0 | 0.00% |
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR3.50 | 0.90% |
2019 | INR3.50 | 1.00% |
2020 | INR3.50 | 1.38% |
2021 | INR3.50 | 0.73% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SMLT.NS | Dividend Knight | 2023-08-09 | Semi-Annually | 3 | 0.64% | |
MGEL.NS | Dividend Junior | 2023-08-08 | Annually | 5 | 0.59% | |
GULPOLY.NS | Dividend Junior | 2023-09-22 | Annually | 10 | 0.67% | |
BBTCL.NS | Dividend Junior | 2023-09-22 | Annually | 4 | 0.35% | |
PTL.NS | Dividend Knight | 2023-07-14 | Annually | 17 | 4.33% | |
KCP.NS | Dividend Junior | 2023-08-10 | Annually | 23 | 0.55% | |
EIHOTEL.NS | Dividend Junior | 2023-08-02 | Annually | 29 | 0.17% | |
ADVENZYMES.NS | Dividend Junior | 2023-08-04 | Annually | 8 | 0.59% | |
SUNPHARMA.NS | Dividend Junior | 2023-07-28 | Semi-Annually | 29 | 0.77% | |
NATIONALUM.NS | Dividend Knight | 2023-09-15 | Semi-Annually | 26 | 4.12% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.156 | 1.500 | 6.87 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.328 | 1.500 | 7.46 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 57.27 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 14.57 | 2.00 | 2.71 | 5.43 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.470 | 1.000 | 5.49 | 5.49 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.224 | 1.000 | 7.53 | 7.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.78 | 1.000 | 8.91 | 0 | [1 - 100] |
returnOnEquityTTM | 0.328 | 2.50 | 8.37 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 5.43 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.324 | 1.500 | -5.49 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0775 | 1.000 | -0.562 | 0 | [0.1 - 0.5] |
Total Score | 3.01 |
Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators